Annual Reports in Medical Chemistry, Vol. 44

Contents

1 Recent advances in the discovery of GSK-3 inhibitors and a perspective on their utility for the treatment of Alzheimer's disease
Robert G. Gentles, Shuanghua Hu, and. Gene Dubowchik

2 Advances in the Development of Nitric Oxide Synthase Inhibitors
Shawn Maddaford, Subhash Annendi, Jailall Remnauth, and Suman Rakhit

3 Small Molecule Protein?Protein Interaction Inhibitors as Therapeutic Agents for Neurodegenerative Diseases: Current Progress and Future Hurdles
Simon Haydar and Warren Hirst

4 Case History: Chantix (varenicline tartrate) a Nicotinic Partial Agonist Aid to Smoking Cessation
Jotham W. Coe, Hans Rollema and Brian T. O'Neill

5 Case History on Tekturna /Rasilez (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension
Juergen Maibaum and David Feldman

6 Advances in Vasopressin Receptor Agonists and Antagonists. Thomas Ryckmans

7 The Emergence of GPR119 Agonists as Anti-diabetic Agents. Robert Jones

8 Non-peptide Ligands for the Gonadotropin Receptors. Nicole van Straten, Marco Timmers

9 Recent Advances in Coagulation Serine Protease Inhibitors
Mimi Quan and Joanne Smallheer

10 Advances in the Discovery of Anti-Inflammatory FMS Inhibitors. Mark Player and Carl Manthey

11 Recent Advances in the Discovery of CB2 Selective Agonists. Jayant Thatte, Sangdon Han, and Rob Jones

12 Advances in the Discovery of Small Molecule JAK3 Inhibitors. Stephen Wrobleski

13 Recent Advances in Adenosine Receptor (AR) Ligands in Pulmonary Diseases
Jeff Zablocki and Rao Kalla

14 Recent Progress in the Development of Small Molecule Inhibitors of Insulin-like Growth Factor Receptor (IGF-1R). Kinase Dinesh Vyas and Mark Wittman

15 Case History: Discovery of Ixabepilone (IXEMPRA[TM]), a First-inclass Epothilone Analogue for Treatment of Metastatic Breast Cancer
Robert M. Borzilleri and Gregory D.

16 Hedgehog Signaling Pathway Inhibitors as Cancer Therapeutics. Stefan Peuker and Karen Miller-Moslin

17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases (PI3Ks)
John M. Nuss, Amy Lew Tsuhako and Neel K. Anand Exelixis

18 Anti-infective Activity of Artemisinin and its Semi-synthetic Derivatives. John G. D'Angelo

19 Recent Advances in the Inhibition of Bacterial Type II Topoisomerases
Greg Bisacchi & Jacques Dumas

20 Progress Towards the Discovery and Development of Specifically Targeted Inhibitors of Hepatitis C Virus
Nicholas A. Meanwell John F. Kadow and Paul M. Scol

21 Inhibitors of Nuclear Hormone Receptor/Steroid Receptor Coactivator Interactions
Terry Moore, John Katzenellenbogen

22 Safety Testing of Drug Metabolites. Tom Thompson

23 A Path to Innovation: Gene Knockouts Model New Drug Action. Brian Zambrowicz

24 Discovery of Novel Positron Emission Tomography (PET) Tracers. Dennis McCarthy

25 The Use of Isotopically Labeled Compounds in Drug Discovery (Chad). Charles S. Elmore

26 Mechanism based inhibition of CYP3A4 and other cytochromes P450. Bernard Murray

27 Nonclinical Toxicogenomics in the Pharmaceutical Environment. Bruce D. Car

28 To Market, To Market 2008. Shridhar Hegde and Michelle Schmidt